Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 9Nivolumab 5aldesleukin 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Interleukin-2 2Cyclophosphamide 2Biopsy 2sargramostim 1relatlimab 1regorafenib 1prednylidene 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1deltacortene 1avelumab 1aflibercept 1X-Rays 1Sirolimus 1Sentinel Lymph Node Biopsy 1Radiotherapy 1Prednisone 1Predictive Learning Models 1Paclitaxel 1Opdualag 1NEO212 1Lidocaine, Prilocaine Drug Combination 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Merkel Cell × Lidocaine, Prilocaine Drug Combination × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡